RopackiMTHannesdottirKHendrixS. Clinically meaningful outcomes in early Alzheimer disease: a consortia-driven approach to identifying what matters to patients. Therapeutic Innovation & Regulatory Science. 2017;51:380–390.
2.
CoonsSJKothariSMonzBUBurkeLB. The Patient-Reported Outcome (PRO) Consortium: filling measurement gaps for PRO end points to support labeling claims. Clin Pharmacol Ther. 2011;90:743–748.
3.
GordonMFLenderkingWRDuhigA. Development of a patient-reported outcome instrument to assess complex activities of daily living and interpersonal functioning in persons with mild cognitive impairment: the qualitative research phase. Alzheimers Dement. 2016;12:75–84.
4.
RaghavanNSamtaniMNFarnumM, et al. The ADAS-Cog revisited: novel composite scales based on ADAS-Cog to improve efficiency in MCI and early AD trials. Alzheimers Dement. 2013;9(1)(suppl):S21–S31.
5.
WangJLogovinskyVHendrixS. ADCOMS: a composite clinical outcome for prodromal Alzheimer’s disease trials. J Neurol Neurosurg Psychiatry. 2016;87:993–999.
6.
WesselsAMSiemersERYuP. A combined measure of cognition and function for clinical trials: the Integrated Alzheimer’s Disease Rating Scale (iADRS). J Prev Alz Dis. 2015;2:227–241.
7.
HuangYItoKBillingCBJrAnzianoRJ; Alzheimer’s Disease Neuroimaging Initiative. Development of a straightforward and sensitive scale for MCI and early AD clinical trials. Alzheimers Dement. 2015;11:404–414.
8.
LlanoDALaforetGDevanarayanV; Alzheimer’s Disease Neuroimaging Initiative. Derivation of a new ADAS-cog composite using tree-based multivariate analysis prediction of conversion from mild cognitive impairment to Alzheimer disease. Alzheimer Dis Assoc Disord. 2011;25:73–84.
9.
HannesdottirKAshwoodTOlssonT, et al. Psychometric features of the ADAS-Cog: identifying a potential cognition endpoint for prodromal Alzheimer’s disease. Alzheimers Dement. 2013;9(4)(suppl):P461.
